Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Chronically infected with HCV genotype 1
HCV treatment-naïve
Not co-infected with HIV or HBV
HCV RNA viral load of at least 100,000 IU/mL
BMI 19 to 35 kg/m2
Subject agrees to use highly effective contraception methods if female of childbearing potential or sexually active male.
You may not be if
History of clinically-significant illness or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol
Decompensated liver disease or cirrhosis or evidence of hepatocellular carcinoma
Serological evidence of co-infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype
Subjects with known, current use of amphetamines and/or cocaine; subjects taking methadone or buprenorphine (opioid replacement therapy) or ongoing alcohol abuse
Clareo Health | A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
